ETF Managers Group, LLC Ionis Pharmaceuticals Inc Transaction History

ETF Managers Group, LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 23, 2023	BUY	$37.12 - $46.52 $283,930 - $355,831	7,649 New	7,649 $288,000
Q2 2021 Aug 16, 2021	SELL	$34.54 - $47.25 $240,916 - $329,568	-6,975 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$42.51 - $63.78 $39,874 - $59,825	938 Added 15.54%	6,975 $312,000
Q4 2020 Feb 16, 2021	BUY	$45.3 - $60.27 $30,758 - $40,923	679 Added 12.67%	6,037 $345,000
Q3 2020 Nov 16, 2020	BUY	$47.45 - $62.95 $12,574 - $16,681	265 Added 5.2%	5,358 $260,000
Q2 2020 Aug 14, 2020	BUY	$46.85 - $61.05 $79,551 - $103,662	1,698 Added 50.01%	5,093 $303,000
Q1 2020 May 14, 2020	BUY	$41.6 - $63.4 $14,476 - $22,063	348 Added 11.42%	3,395 $164,000
Q4 2019 Feb 14, 2020	BUY	$53.85 - $65.27 $37,856 - $45,884	703 Added 29.99%	3,047 $184,000
Q3 2019 Nov 14, 2019	BUY	$59.06 - $72.15 $2,716 - $3,318	46 Added 2.0%	2,344 $138,000
Q2 2019 Aug 14, 2019	SELL	$62.09 - $86.14 $58,923 - $81,746	-949 Reduced 29.23%	2,298 $149,000
Q1 2019 May 07, 2019	BUY	$52.92 - $81.17 $15,399 - $23,620	291 Added 9.84%	3,247 $264,000
Q4 2018 Feb 01, 2019	BUY	$43.37 - $59.54 $17,434 - $23,935	402 Added 15.74%	2,956 $160,000
Q3 2018 Nov 14, 2018	BUY	$42.88 - $53.7 $11,491 - $14,391	268 Added 11.72%	2,554 $132,000
Q2 2018 Aug 14, 2018	BUY	$40.53 - $50.7 $21,764 - $27,225	537 Added 30.7%	2,286 $1.3 Million
Q1 2018 May 15, 2018	BUY	$44.08 - $55.05 $9,609 - $12,000	218 Added 14.24%	1,749 $74,000
Q4 2017 Feb 14, 2018	BUY	$50.3 - $64.39 $10,965 - $14,037	218 Added 16.6%	1,531 $75,000
Q3 2017 Nov 14, 2017	BUY	$45.56 - $59.57 $59,820 - $78,215	1,313	1,313 $67,000

389

125M

2.25M

510K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.64B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

Stay updated on ETF Managers Group, LLC with notifications on news.